GLP1R and nephrolithiasis: We postulate that therapies targeting adipose depots, for example, glucagon-like peptide-1 receptor agonists, may affect calcium homeostasis and have utility for the prevention of kidney stone disease.61, , –64 Studies are required to investigate these mechanisms and reveal novel therapeutic targets to facilitate improved management strategies for patients with kidney stone.65